Safety and Clinical Outcomes when Utilizing High-Dose (≥8 mg/kg) Daptomycin Therapy

Abstract

Spanish

French

Background:

Daptomycin is approved for the treatment of skin and skin-structure infections (4 mg/kg) and Staphylococcus aureus bacteremia, including right-sided endocarditis (β mg/kg). In vitro and animal studies have reported increased activity with increased daptomycin doses. There are limited clinical data on use of daptomycin at doses greater than 6 mg/kg.

Objective:

To evaluate the safety and efficacy of higher doses (≥8 mg/kg) of daptomycin when administered for a variety of gram-positive infections.

Methods:

Data were collected retrospectively as part of an ongoing registry (the Cubicin Outcomes Registry and Experience database) for the 2005–2007 program years. For the purpose of this study, the safety and efficacy of daptomycin were evaluated in patients who received doses of 8 m/kg or higher.

Results:

Ninety-four (2.6%) of 3617 patients received daptomycin doses of 6 mg/kg or higher; 18 (19%) of those patients received doses of 10 mg/kg or higher. The most common infections were bacteremia (30/94), skin and skin-structure infections (22/94), and endocarditis (15/94). The most common pathogens were Enterococcus spp. (37/94; 57% vancomycin-resistant) and S. aureus (28/94; 68% methicllin-resistant). Fifty-one percent of the patients were male. 39% were aged 66 years or older, 27% had an initial creatinine clearance less than 30 mL/min, and 17% were on dialysis. The median duration of daptomycin therapy was 15 days (minimum 1, maximum 90). Six (6.4%) of the 94 patients experienced 1 or more adverse events or abnormal laboratory value changes possibly related to daptomycin; in 2 (2.1%) of the 94 patients, daptomycin was discontinued due to treatment-related adverse events. Seventy-four (79%) patients were considered evaluable for efficacy. The overall clinical success rate was 89% (bacteremia, 91 %; skm and skin-structure infections. 88%: endocarditis. 67%)

Conclusions:

Daptomycin was well tolerated and effective at doses of 8 mg/kg or higher in patients with gram-positive infections. Further prospective and comparative studies of daptomycin at doses greater than 6 mg/kg are warranted.

Keywords

daptomycin higher doses gram-positive infections

Get full access to this article

View all access options for this article.

References

Rennie

Jones

Mulnick

. Occurrence of antimicrobial susceptibility patterns of pathogens isolated from skin and soft tissue infections: report from the SENTRY antimicrobial surveillance program (United States and Canada, 2000). Diagn Microbiol Infect Dis 2003;45:287–93.

Moran

Krishnadasan

Gorwitz

. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006;355:666–74.

Edmond

Wallace

McClish

Pfaller

Jones

Wenzel

. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis 1999;29:239–44.

Levine

. Vancomycin: understanding its past and preserving its future. South Med J 2008;101:284–91.

Sakoulas

Moellering

Jr. . Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains. Clin Infect Dis 2008;46(suppl 5):S360–7.

Boucher

Corey

. Epidemiology of methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2008;46(suppl 5):S344–9.

Chang

Peacock

Jr.

Musher

. Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine (Baltimore) 2003;82:333–9.

Fowler

Jr.

Kong

Corey

. Recurrent Staphylococcus aureus bacteremia: pulsed-field gel electrophoresis findings in 29 patients. J Infect Dis 1999;179: 1157–61.

Levine

Fromm

Reddy

. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 1991;115:674–80.

10.

Sakoulas

Moise-Broder

Schentag

Forrest

Moellering

Jr.

Eliopoulos

. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004;42:2398–402.

11.

Moise-Broder

Sakoulas

Eliopoulos

Schentag

Forrest

Moellering

Jr. . Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin Infect Dis 2004;38:1700–5.

12.

Fowler

Jr.

Sakoulas

McIntyre

. Persistent bacteremia due to methicillin-resistant Staphylococcus aureus infection is associated with agr dysfunction and low-level in vitro resistance to thrombin-induced platelet microbicidal protein. J Infect Dis 2004;190:1140–9.

13.

Hidayat

Hsu

Quist

Shriner

Wong-Beringer

. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006;166:2138–44.

14.

Moise

Sakoulas

Forrest

Schentag

. Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2007;51:2582–6.

15.

Soriano

Marco

Martinez

. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008;46:193–200.

16.

Lodise

Graves

Evans

. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 2008;52:3315–20.

17.

Hsu

Hidayat

Quist

. Comparison of method specific vancomycin MIC values and their predictability on treatment outcomes of MRSA infections. Int J Antimicrob Agents 2008;32:378–85.

18.

Snydman

Jacobus

McDermott

Lonks

Boyce

. Comparative in vitro activities of daptomycin and vancomycin against resistant gram-positive pathogens. Antimicrob Agents Chemother 2000;44:3447–50.

19.

Rybak

Hershberger

Moldovan

Grucz

. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin–dalfopristin against Staphylococci and Enterococci, including vancomycin-intermediate and-resistant strains. Antimicrob Agents Chemother 2000;44:1062–6.

20.

Castanheira

Jones

Sader

. Update of the in vitro activity of daptomycin tested against 6710 gram-positive cocci isolated in North America (2006). Diagn Microbiol Infect Dis 2008;61:235–9.

21.

Zhanel

Decorby

Laing

Weshnoweski

Vashisht

Tailor

. Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005–2006. Antimicrob Agents Chemother 2008;52:1430–7.

22.

Sader

Streit

Fritsche

Jones

. Antimicrobial susceptibility of gram-positive bacteria isolated from European medical centers: results of the Daptomycin Surveillance Program (2002–2004). Clin Microbiol Infect 2006;12:844–52

23.

Marty

Yeh

Wennersten

. Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis. J Clin Microbiol 2006;44:595–7.

24.

Skiest

. Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin. J Clin Microbiol 2006;44:655–6.

25.

Vikram

Havill

Koeth

Boyce

. Clinical progression of methicillin-resistant Staphylococcus aureus vertebral osteomyelitis associated with reduced susceptibility to daptomycin. J Clin Microbiol 2005;43:5384–7.

26.

Mariani

Sader

Jones

. Development of decreased susceptibility to daptomycin and vancomycin in a Staphylococcus aureus strain during prolonged therapy. J Antimicrob Chemother 2006;58:481–3.

27.

Safdar

Andes

Craig

. In vivo pharmacodynamics activity of daptomycin. Antimicrob Agents Chemother 2004;48:63–8.

28.

Rose

Leonard

Rybak

. Evaluation of daptomycin pharmacodynamics and resistance at various dosage regimens against Staphylococcus aureus isolates with reduced susceptibilities to daptomycin in an in vitro pharmacodynamics model with simulated endocardial vegetations. Antimicrob Agents Chemother 2008;52:3061–7.

29.

Rose

Rybak

Kaatz

. Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategics. J Antimicrob Chemother 2007;60:334–40.

30.

Chambers

Basuino

Diep

. Relationship between susceptibility to daptomycin in vitro and activity in vivo in a rabbit model of aortic valve endocarditis. Antimicrob Agents Chemother 2009;53:1463–7.

31.

Dvorchik

Brazier

DeBruin

Arbeit

. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother 2003;47:1318–23.

32.

Benvenuto

Benziger

Yankelev

Vigliani

. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother 2006;50:3245–9.

33.

Katz

Lindfield

Steenbergen

. A pilot study of high-dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by gram-positive bacteria. Int J Clin Pract 2008;62:1455–64.

34.

Cunha

Krol

Kodali

. Methicillin-resistant Staphylococcus aureus (MRSA) mitral valve acute bacterial endocarditis (ABE) in a patient with Job's syndrome (hyperimmunoglobulin E syndrome) successfully treated with linezolid and high-dose daptomycin. Heart Lung 2006;35:207–11.

35.

Figueroa

Mangini

Amodio-Groton

. Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program. Clin Infect Dis 2009;49:181–3.

36.

Alam

Jimenez

. Daptomycin for the treatment of persistent vancomycin resistant Enterococcus (VRE) bacteremia and/or infective endocarditis (IE) that failed to respond to currently available therapeutics. Presented as a poster at the 45th Annual Meeting of the Infectious Diseases Society of America meeting, San Diego, CA, October 4, 2007.

37.

Golik

Lawrence

Golan

. High dose daptomycin in patients with severe infections: efficacy and tolerability. Presented as a poster at the Inter-science Conference on Antimicrobial Agents and Chemotherapy/Infectious Diseases Society of America, Washington, DC, October 26, 2008.

38.

Kullar

Davis

Levine

. High-dose daptomycin for complicated gram-positive infections. Presented as a poster at: 19th European Congress of Clinical Microbiology and Infectious Diseases, Helsinki, Finland, May 19, 2009.

39.

Rolston

Segreti

Lamp

Friedrich

. Cubicin outcomes registry and experience (CORE) methodology. Am J Med 2007;120(suppl 10A): S4–5.

40.

Fowler

Jr.

Boucher

Corey

. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006;355:653–65.

41.

Vikram

Buenconsejo

Hasbun

Quagliarello

. Impact of valve surgery on 6-month mortality in adults with complicated, left-sided native valve endocarditis: a propensity analysis. JAMA 2003;290:3207–14.

42.

Tally

Zeckel

Wassilewski

. Daptomycin: a novel agent for gram-positive infections. Exp Opin Investig Drugs 1999;8:1223–38.

43.

Arbeit

Maki

Tally

. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004;38:1673–81.